Consolidated September 2026 quarter revenue rises 31% and profit turns positive
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue was Rs 5,813.39 lakh, up 30.8% from Rs 4,444.92 lakh a year earlier, and profit after tax was Rs 67.49 lakh versus a Rs 56.03 lakh loss. Standalone quarter revenue was Rs 57.50 lakh versus Rs 78.92 lakh a year earlier, with a Rs 3.03 lakh loss versus Rs 38.23 lakh. Consolidated half-year revenue was Rs 10,169.65 lakh and profit after tax Rs 465.07 lakh, down from Rs 766.32 lakh.
Positive: revenue rose 31% and quarterly profit turned positive, but half-year profit fell to Rs 465.07 lakh from Rs 766.32 lakh.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.